RCC, also referred to as kidney cancer, develops in the kidney’s tubules, which are where urine is produced and waste is removed from the circulation. Immune checkpoint inhibitors (ICIs), such as programmed death-1 (PD-1) blockers (pembrolizumab and nivolumab), are frequently used as first-line treatments for RCC patients. However, a large number of patients relapse or do not benefit from ICI interventions. Due to the high percentage of ICI failure in RCC patients, it is urgently necessary to look for new therapeutic approaches that have been shown to be safe and effective in patients who have previously received immunotherapy. One of these therapy regimens was recently examined by a research team, and the findings of their study were reported in The Lancet Oncology.